AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17234675
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine 25 mg-prilocaine 25 mg/G) applied to the uterine cervix 30 min before HSG
Trial: 17234675
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied to the uterine cervix 30 min before HSG
Trial: 7855193
Drug: Alcohol group
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol group A (0.62 g/kg) with withholding knowledge of results (KR)
Trial: 7855193
Drug: Alcohol group
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol group AM (0.62 g/kg) with incentive for nonimpaired performance
Trial: 27965882
Drug: Optimal Personalised
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Personalised Care After Treatment for Gynaecological cancer (OPCAT-G) intervention
Trial: 25211663
Drug: HER2/neu positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2/neu positive status in sigmoideal and rectal carcinomas
Trial: 21807750
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control condition receiving treatment as usual
Trial: 19001323
Drug: Consolidation docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation docetaxel 75 mg/m2 IV every 21 days for three cycles
Trial: 16430387
Drug: Pill counting
RxNorm normalized name: Pill Counting Tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill counting
Trial: 1673478
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 mcg.kg‐1)
Trial: 1673478
Drug: Verapamil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (50 mcg.kg‐1)
Trial: 1673478
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no Ca entry blocker)
Trial: 31701799
Drug: rosiglitazone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone with metformin (R + M)
Trial: 25744509
Drug: High amylose
RxNorm normalized name: hydroxypropyl distarch phosphate, high amylose corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High amylose maize resistant starch (RS) incorporated into fried wheat flour dough, given twice daily for 28 days.
Trial: 24885993
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of transfluthrin coils and deltamethrin LLINs
Trial: 30986735
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors (MAOIs)
Trial: 15169848
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ascorbic acid (500 mg day(‐1)) and RRR‐alpha‐tocopherol (400 i.u. day(‐1))
Trial: 11489683
Drug: Bicalutamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (150 mg daily)
Trial: 7981579
Drug: Nicotine 0.014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 0.014 mg/kg body weight
Trial: 7981579
Drug: Nicotine 0.028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 0.028 mg/kg body weight
Trial: 7981579
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/kg body weight)
Trial: 4666629
Drug: Intra-amniotic prostaglandin
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic prostaglandin F2α and intravenous oxytocin
Trial: 27429113
Drug: Combined alfacalcidiol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined alfacalcidiol and metformin therapy (Group 2)
Trial: 27429113
Drug: Metformin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (Group 3)
Trial: 23174632
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor
Trial: 20420643
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily calcineurin inhibitor (CNI) monotherapy at half their previous dose
Trial: 20420643
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily calcineurin inhibitor (CNI) monotherapy
Trial: 1651738
Drug: Low-dose ANP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ANP infusion (0.005 microgram/kg/min for 1 h)
Trial: 1651738
Drug: High-dose ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ANP infusion (0.05 microgram/kg/min for 1 h)
Trial: 6341102
Drug: Ketotifen 2
RxNorm normalized name: ketotifen 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 2 mg daily per os
Trial: 6341102
Drug: Oral disodium
RxNorm normalized name: etidronate disodium Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disodium cromoglycate
Trial: 31210177
Drug: Tavipec® (Spicae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tavipec® (Spicae aetheroleum) 150 mg, 2 capsules thrice daily for 7 days
Trial: 18812447
Drug: Sildenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil treatment
Trial: 23030673
Drug: Water ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water ingestion (50 mL)
Trial: 23030673
Drug: Water ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water ingestion (500 mL)
Trial: 17147487
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (CI) in excess of 1039 mg/day
Trial: 11927731
Drug: DTPa-HBV-IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV vaccine coadministered with Hib vaccines (groups 1-4)
Trial: 11927731
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available control vaccines (DTPa, Hib, and OPV) administered separately (group 5)
Trial: 16709537
Drug: DTPa-HBV-IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV vaccine
Trial: 11927731
Drug: Hib N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib N meningitidis outer-membrane complex protein conjugate vaccine
Trial: 10216145
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (9 million units three times a week for 38 +/- 8 weeks or 49 +/- 13 weeks)
Trial: 10216145
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (44.8 +/- 27.4 weeks)
Trial: 8785887
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with calcipotriene
Trial: 92202
Drug: Indirect treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect treatment away from the leak
Trial: 25346345
Drug: Pivotal Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal Response Treatment Group (PRTG)
Trial: 20020572
Drug: Lasofoxifene 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 0.5 mg
Trial: 15231008
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (500 IU/day) and calcium (500 mg/day) during winter months (October-April)
Trial: 16684385
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (control group)
Trial: 11420592
Drug: Suctioning techniques
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suctioning techniques (including preoxygenation, hyperinflation, insufflation, hyperoxygenation, hyperventilation, saline instillation, adaptor use, medication use, open and closed systems, and various types of catheters)
Trial: 2870956
Drug: Terbutaline 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.25 +/- 0.25 mg iv
Trial: 2870956
Drug: Prenalterol 1
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol 1 mg iv
Trial: 2870956
Drug: Metoprolol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 15 mg iv (pretreatment)
Trial: 2870956
Drug: Propranolol 10
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 10 mg iv (pretreatment)
Trial: 2870956
Drug: Metoprolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol infusion
Trial: 30074128
Drug: Prasugrel 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 2.5 mg/day
Trial: 24808022
Drug: Corticosteroids alone
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids alone or in combination with cardioprotective medication
Trial: 22825506
Drug: DC/CIK immunobiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC/CIK immunobiological cancer therapy
Trial: 22825506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DC/CIK treatment)
Trial: 16160068
Drug: Standard initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation dose of 5 mg warfarin/day
Trial: 16160068
Drug: Model-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based dosing using rapid CYP2C9 genotyping
Trial: 16160068
Drug: Model-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based dosing
Trial: 9049193
Drug: Norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 400 mg daily administered orally (group 1)
Trial: 3098141
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium cromoglycate (SCG) administered for 8 weeks
Trial: 3098141
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered for 8 weeks
Trial: 29678563
Drug: FIT Teens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT Teens (integrated Cognitive-Behavioral Therapy and specialized neuromuscular exercise training)
Trial: 26896828
Drug: BIIB023 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB023 (3 or 20 mg kg(‐1) administered by intravenous infusion on Day 1)
Trial: 23601577
Drug: 600-mg loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg loading dose of clopidogrel 4 to 8 hours before PCI (n=122)
Trial: 19081397
Drug: 600-mg loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg loading dose of clopidogrel
Trial: 14616928
Drug: naratriptan 2.5
RxNorm normalized name: naratriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naratriptan 2.5 mg
Trial: 11833825
Drug: Intranasal influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal influenza vaccine (groups AI, AII, AIII)
Trial: 11833825
Drug: Intramuscular virosomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular virosomal subunit vaccine (group B)
Trial: 10073636
Drug: Control lenses
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Control lenses (subjects' own daily wear soft lenses)
Trial: 7710021
Drug: Pre-operative measurement
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative measurement using paracetamol absorption technique
Trial: 7710021
Drug: Post-operative measurement
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative measurement using paracetamol absorption technique
Trial: 1975334
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg cromakalim
Trial: 1975334
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg cromakalim
Trial: 31760314
Drug: Erythrocyte-encapsulated asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with gemcitabine or mFOLFOX6
Trial: 31760314
Drug: Erythrocyte-encapsulated asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy
Trial: 19716144
Drug: Omegaven (4-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omegaven (4-hour lipid infusion contributing 0.04 g/kg of marine n-3 FA)
Trial: 19716144
Drug: Intralipid (4-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (4-hour lipid infusion)
Trial: 17978709
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antiplatelet therapy during surgery
Trial: 17978709
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antiplatelet therapy and substitution with flurbiprofen or isocoagulant fractionated heparin or calcium heparin
Trial: 9205764
Drug: ebrotidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebrotidine 400 mg
Trial: 9205764
Drug: ebrotidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebrotidine 400 mg (smokers)
Trial: 9205764
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg (smokers)
Trial: 8485019
Drug: BRL 46470A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 46470A (0.1 microgram, 0.01 mg, 1 mg or 50 mg)
Trial: 2889678
Drug: Procaterol 20
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol 20 mcg
Trial: 2889678
Drug: Fenoterol 400
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 400 mcg
Trial: 12025709
Drug: Supplementary written
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary written drug information
Trial: 12025709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplementary written drug information)
Trial: 7115656
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid supplements (20 mg elemental Fe and 0.1 mg folic acid daily for 60 days)
Trial: 7115656
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid supplements (40 mg Fe and 0.2 mg folic acid daily in two divided doses for 60 days)
Trial: 31272709
Drug: Fruquintinib 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 4 mg in fed state
Trial: 28328324
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg per day adjusted to a maximum of 600 mg per day)
Trial: 26321593
Drug: Inhaled epinephrine
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled epinephrine
Trial: 17762286
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg triamcinolone
Trial: 1991216
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg triamcinolone
Trial: 16112241
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (LANTUS) at bedtime plus previous oral hypoglycaemic agents (OHAs)
Trial: 16112241
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (LANTUS)
Trial: 3298136
Drug: Busulfan (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (induction therapy)
Trial: 18209510
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg twice a day)
Trial: 17016190
Drug: Single-injection volar
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection volar subcutaneous block
Trial: 17016190
Drug: Two-injection dorsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-injection dorsal block
Trial: 11012470
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Lansoprazole 30 mg taken 15 min before breakfast
Trial: 11012470
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Lansoprazole 30 mg taken without a meal
Trial: 8975939
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/day) from 5th postoperative week for one year
Trial: 8975939
Drug: Epirubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (40 mg/m2) bolus injection arterially on day 28, in addition to UFT administration
Trial: 1335638
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (CLF strain, 360 ELISA units, 0.5 mg aluminium hydroxide)
Trial: 1335638
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (HM175 strain, 180 ELISA units, 1 mg aluminium hydroxide)
Trial: 1335638
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (HM175 strain, 360 ELISA units, 0.5 mg aluminium hydroxide)
Trial: 1335638
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (HM175 strain, 360 ELISA units, 1 mg aluminium hydroxide)
Trial: 1335638
Drug: Group E
RxNorm normalized name: Prostaglandin group E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E (HM175 strain, 720 ELISA units, 1 mg aluminium hydroxide)
Trial: 380631
Drug: Doxycycline (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (first treatment)
Trial: 15936036
Drug: Sham infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham infusion
Trial: 30791557
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of Polydextrose per day
Trial: 30791557
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g of Polydextrose per day
Trial: 30791557
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of Polydextrose per day
Trial: 27830395
Drug: Glutamine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (6 g/m2 per dose twice daily, maximum 10 g/dose)
Trial: 15924620
Drug: High-intensity exercise
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity exercise program (twice weekly, one hour sessions for six weeks, performed at >= 60% of maximum heart rate)
Trial: 12511367
Drug: IOP reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP reduction achieved by medical, laser, or surgical therapy in OAG patients
Trial: 12511367
Drug: IOP reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP reduction achieved by medical, laser, or surgical therapy in OHT patients
Trial: 1708961
Drug: Early suckling
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early suckling (treatment group)
Trial: 373903
Drug: Mefloquine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (1.5 g)
Trial: 373903
Drug: Pyrimethamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (75 mg) plus sulfadoxine (1.5 g)
Trial: 27941065
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg every 2 weeks)
Trial: 29566128
Drug: Evolocumab (monotherapy)
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab (monotherapy)
Trial: 29566128
Drug: Evolocumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (in combination with atorvastatin)
Trial: 29566128
Drug: Evolocumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab and atorvastatin (substudy of 16 subjects)
Trial: 24035299
Drug: Controlled temporary
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled temporary phrenic nerve palsy induced by local administration of lidocaine 1% at a rate of 3 mL/h (30 mg/h) via catheter.
Trial: 12768300
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg, two times per day)